Skip to main content
main-content

01.01.2019 | Original Paper | Ausgabe 1/2019

Medical Oncology 1/2019

The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma

Zeitschrift:
Medical Oncology > Ausgabe 1/2019
Autoren:
Alexandre A. B. A. da Costa, Felipe D’Almeida Costa, Daniel Vilarim Araújo, Marcos Pedro Guedes Camandaroba, Victor Hugo Fonseca de Jesus, Audrey Oliveira, Ana Caroline Fonseca Alves, Carlos Stecca, Larissa Machado, Andrea Cruz Feraz de Oliveira, Thiago Bueno de Oliveira, Ulisses Ribaldo Nicolau, Vladmir Cláudio Cordeiro de Lima
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s12032-018-1234-0) contains supplementary material, which is available to authorized users.

Abstract

There is no established biomarker for cetuximab efficacy in recurrent head and neck squamous cell carcinoma (HNSCC). The aim of the present study was to evaluate the prognostic and predictive impact of PTEN, cMET, and p16 expression in recurrent HNSCC. In this retrospective study, 112 patients with recurrent HNSCC received chemotherapy (CT) alone (n = 37) or chemotherapy with cetuximab (n = 75). PTEN, cMET, and p16 protein expression were evaluated by immunohistochemistry. The median overall survival (mOS) for the patients treated with cetuximab + CT versus CT alone was 11.4 months and 7.0 months, (p = 0.949). The median progression-free survival (mPFS) was 6.2 months versus 3.0 months (p = 0.154). Patients with PTEN loss exhibited a mOS of 5.8 months versus 10.5 months (p = 0.002) and a mPFS of 3.2 months versus 4.7 months (p = 0.019). A multivariate analysis identified an independent association between PTEN loss and OS (HR 2.27; 95% confidence 95% CI 1.27–4.08; p = 0.006) and with PFS (HR 1.85; 95% CI 1.09–2.99; p = 0.022). A negative prognostic impact of PTEN loss was observed in the patients treated with cetuximab + CT, and not in the CT only group. Expression of cMET and p16 showed no impact on OS or PFS. The present findings confirm that PTEN is a prognostic factor for metastatic HNSCC and they support further studies of PTEN expression to evaluate its predictive value to cetuximab response.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Kaplan-Meier curves for overall survival according to ECOG performance status (A), smoking history (B), and type of recurrent disease (C). Progression-free survival according to age at diagnosis (D). Supplementary material 1 (JPG 423 KB)
12032_2018_1234_MOESM1_ESM.jpg
Kaplan-Meier curves for overall survival and progression-free survival according to CMET expression (A and C) and p16 expression (B and D) are presented, respectively in each case. Supplementary material 2 (JPG 413 KB)
12032_2018_1234_MOESM2_ESM.jpg
Supplementary material 3 (DOCX 63 KB)
12032_2018_1234_MOESM3_ESM.docx
Supplementary material 4 (DOCX 70 KB)
12032_2018_1234_MOESM4_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2019

Medical Oncology 1/2019 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise